Dedicated Pet Parents and Brave Dogs come together to advance Lifesaving Research.

Thanks to the courage of the dogs and families who donated tumor samples, researchers have made a major step forward in developing new cancer treatments for pets. In this groundbreaking study, PennVet scientists discovered that dogs’ tumors contain powerful immune cells — called tumor‑infiltrating lymphocytes (TILs) — that can be collected, grown, and activated to recognize and attack cancer.

This is a big deal. Until now, we didn’t know whether TIL therapy, which has helped human melanoma patients, could work in dogs with cancers like oral melanoma and osteosarcoma — diseases that affect many sighthounds and are often difficult to treat.

The study found that:

  1. It is feasible to isolate T cells from osteosarcoma samples and generat functional TIL products from them.

  2. TILs expanded from some patients were able to kill that patient’s tumor cells
In everyday terms: Your dogs’ donated samples proved that their immune cells can be trained to fight their own cancer — opening the door to future personalized treatments.

🐾 GHI’s Role in Making This Possible

The Greyhound Health Initiative is proud to partner with PennVet, Dr. Nicola Mason, and Dr. Kay Foos to help recruit canine patients for this research. Because of this partnership — and because of the generosity of sighthound families — scientists now have the evidence they need to move toward clinical trials and new therapeutic options.

🔬 The Work Isn’t Finished — New Participants Are Needed

This research is ongoing, and more dogs are needed to continue advancing TIL therapy. Samples are also being used to determine sensitivity of each dog’s tumor to particular chemotherapies. This work is in its early stages but advances are being made. Every new participant helps researchers refine the process, understand which cancers respond best, and bring us closer to treatments that could give sighthounds more time and better outcomes.

📘 Learn More About Current Research

You can explore our active studies, ongoing collaborations, and educational resources below. Your support — and your dogs’ bravery — are directly shaping the future of cancer care.  Read the full article below.

 
OSA clinical trial
 

PennVet is now enrolling dogs newly diagnosed with osteosarcoma in a clinical trial evaluating iNKT‑cell–based therapy.  This trial will pay for amputation, standard of care chemo and more.  Click to see whether your pet qualifies.

OSA Research tissue study mason
 

PennVet & CHOP research teams are exploring a new cell-based immunotherapy for dogs with OSA. Fresh tumor samples collected during amputation are needed for processing. Click here for more information on participating in this study.

OSA Biomarkers Research Info
 

This IDEXX Labs study is working to detect osteosarcoma before symptoms appear—using just a simple blood sample. If your dog has been diagnosed and you’d like to contribute to this important research, click to learn more.

Metastatic OSA clinical trial info
 

If your dog has been diagnosed with metastatic osteosarcoma, they may be eligible for a clinical trial at PennVet. This study explores a promising immunotherapy designed to slow disease progression and reduce lung metastases.

   

Learn More about Osteosarcoma

Nothing Found

 

  • Postoperative Adjuvant Combination Therapy with Doxorubicin and Noncytotoxic Suramin in Dogs with Appendicular Osteosarcoma

    — —

  • Genome-wide analyses implicate 33 loci in heritable dog osteosarcoma, including regulatory variants near CDKN2A/B

    — —

  • Retrospective evaluation of the effectiveness of epsilon aminocaproic acid for the prevention of postamputation bleeding in retired racing Greyhounds with appendicular bone tumors: 46 cases (2003–2008)

    — —

  • Characterization of Canine Osteosarcoma by Array Comparative Genomic Hybridization and RT-qPCR: Signatures of Genomic Imbalance in Canine Osteosarcoma Parallel the Human Counterpart

    — —

 
fimmu-17-1810955